For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| General and administrative expenses | 1,742,315 | 2,302,141.5* | 2,044,937 | 2,656,392 |
| Research and development expenses | 771,508 | 1,451,223.5* | 688,465 | 1,077,498 |
| Depreciation expense | 555 | 5,671* | 401 | 401 |
| Total operating expenses | 2,514,378 | 3,759,036 | 2,733,803 | 3,734,291 |
| Loss from operations | -2,514,378 | -3,759,036* | -2,733,803 | -3,734,291 |
| Interest and dividend income | 17,838 | 51,162 | 48,098 | 67,004 |
| Total other income | 17,838 | 51,162* | 48,098 | 67,004 |
| Net loss and comprehensive loss | -2,496,540 | -3,707,874 | -2,685,705 | -3,667,287 |
| Basic EPS | -1.04 | -1.877 | -1.31 | -1.87 |
| Diluted EPS | -1.04 | -1.877 | -1.31 | -1.87 |
| Basic Average Shares | 2,407,665 | 1,975,596 | 2,044,033 | 1,961,642 |
| Diluted Average Shares | 2,407,665 | 1,975,596 | 2,044,033 | 1,961,642 |
Cadrenal Therapeutics, Inc. (CVKD)
Cadrenal Therapeutics, Inc. (CVKD)